Axon Therapy— 510(k) K210021
Substantially EquivalentNeuralace Medical, Inc.
FDA 510(k) clearance K210021 for Axon Therapy, Substantially Equivalent on 2021-06-11. Applicant: Neuralace Medical, Inc..
Clearance details
- Applicant
- Neuralace Medical, Inc.
- Product code
- Code QPL
- Advisory panel
- Neurology
- Date received
- Decision date
- Decision
- Substantially Equivalent
- Clearance type
- Traditional
- Location
- San Diego, CA, US
Data sourced from openFDA. This site is unofficial and independent of the FDA.